CCI-779 in Treating Patients With Metastatic Melanoma

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

June 30, 2001

Primary Completion Date

September 30, 2005

Study Completion Date

September 30, 2005

Conditions
Melanoma (Skin)
Interventions
DRUG

temsirolimus

Trial Locations (21)

10021

Weill Medical College of Cornell University, New York

11030

North Shore University Hospital, Manhasset

46601

CCOP - Northern Indiana CR Consortium, South Bend

60153

Loyola University Medical Center, Maywood

60201

Evanston Northwestern Health Care - Evanston Hospital, Evanston

60426

Ingalls Memorial Hospital, Harvey

60525

LaGrange Memorial Hospital, LaGrange

60640

Louis A. Weiss Memorial Hospital, Chicago

61602

Oncology/Hematology Associates of Central Illinois, P.C., Peoria

62526

Decatur Memorial Hospital Cancer Care Institute, Decatur

62701

Central Illinois Hematology Oncology Center, Springfield

90089

USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles

91105

City of Hope Medical Group, Pasadena

95817

University of California Davis Cancer Center, Sacramento

91010-0269

City of Hope Comprehensive Cancer Center, Duarte

60637-1470

University of Chicago Cancer Research Center, Chicago

46885-5099

Fort Wayne Medical Oncology and Hematology, Incorporated, Fort Wayne

19104-4283

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

L8V 5C2

Cancer Care Ontario-Hamilton Regional Cancer Centre, Hamilton

N6A 4L6

Cancer Care Ontario-London Regional Cancer Centre, London

M5G 2M9

Princess Margaret Hospital, Toronto

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER

NCT00022464 - CCI-779 in Treating Patients With Metastatic Melanoma | Biotech Hunter | Biotech Hunter